Trial · NCT00912912
Sunitinib Malate in Refractory Germ Cell Tumors
NCT00912912, Phase 2, Terminated, M.D. Anderson Cancer Center; results first posted 2016-01-27
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Sunitinib Malate in Refractory Germ Cell Tumors. Trials, record NCT00912912. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00912912
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Sunitinib Malate in Refractory Germ Cell Tumors
- NCT number
- NCT00912912
- Status
- Terminated
- Phases
- Phase 2
- Enrollment
- 5 participants, actual
- Lead sponsor
- M.D. Anderson Cancer Center
- Conditions
- Genitourinary Disease
- Interventions
- Sunitinib Malate
- First posted
- 2009-06-03
- Last updated
- 2016-04-15
- Results first posted
- 2016-01-27
Source ClinicalTrials.gov
Registered outcomes1
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | 12 Week Progression Free Survival Rate in Refractory Germ Cell Tumors Treated With Sunitinib Malate | 12 weeks | Measurable disease or response recorded from start of treatment until disease progression/recurrence. Participants who die during therapy or are lost to follow-up shall be counted as progressive disease. Progressive disease defined as at least a 20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum longest diameter recorded since the treatment started or the appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions. Evaluation of measurable disease response follows Response Evaluation Criteria in Solid Tumors (RECIST) guidelines. |
Source ClinicalTrials.gov
Outcomes1
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | 12 Week Progression Free Survival Rate in Refractory Germ Cell Tumors Treated With Sunitinib Malate | 12 weeks | Percentage of Participants | NUMBER |
Source ClinicalTrials.gov
Results by group1
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| 12 Week Progression Free Survival Rate in Refractory Germ Cell Tumors Treated With Sunitinib Malate | Sunitinib Malate | 20 | Percentage of Participants |
Source ClinicalTrials.gov
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Sunitinib Malate | 5 | |
| Overall Study | COMPLETED | Sunitinib Malate | 1 | |
| Overall Study | NOT COMPLETED | Sunitinib Malate | 4 |
Source ClinicalTrials.gov
Adverse events48
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | CONSTIPATION | Gastrointestinal disorders | Sunitinib Malate | 2 | 5 | 7 |
| other | MOOD ALTERATION (DEPRESSION) | Psychiatric disorders | Sunitinib Malate | 1 | 5 | 1 |
| other | NAUSEA | Gastrointestinal disorders | Sunitinib Malate | 3 | 5 | 5 |
| other | VOMITING | Gastrointestinal disorders | Sunitinib Malate | 2 | 5 | 7 |
| other | FATIGUE | General disorders | Sunitinib Malate | 4 | 5 | 17 |
| other | NEUROPATHY: SENSORY | Nervous system disorders | Sunitinib Malate | 4 | 5 | 5 |
| other | INSOMNIA | General disorders | Sunitinib Malate | 1 | 5 | 1 |
| other | PAIN (OTHER) | General disorders | Sunitinib Malate | 2 | 5 | 3 |
| other | PAIN (EXTREMITY - LIMB) | Musculoskeletal and connective tissue disorders | Sunitinib Malate | 2 | 5 | 2 |
| other | PAIN (ABDOMEN) | Gastrointestinal disorders | Sunitinib Malate | 3 | 5 | 4 |
1 to 10 of 48Source ClinicalTrials.gov
See all 48 adverse eventsAdverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Sunitinib Malate | ||
| Total, other adverse events | Sunitinib Malate | 5 | 5 |
| Total, serious adverse events | Sunitinib Malate | 3 | 5 |
Source ClinicalTrials.gov
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 25085632 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00912912
GET https://conductscience.org/api/trials/v1/NCT00912912/events?page=2